Ciclesonide, sold under the brand name Omnaris among others, is a glucocorticoid used to treat asthma and allergic rhinitis.
Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[6]
It was patented in 1990 and approved for medical use in 2005.[7] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[8] It is on the World Health Organization's List of Essential Medicines.[9]
Society and culture
Brand names
It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.
References
- ^ "Omnaris- ciclesonide spray". DailyMed. 8 November 2022. Retrieved 29 June 2024.
- ^ "Alvesco- ciclesonide aerosol, metered". DailyMed. 16 February 2023. Retrieved 29 June 2024.
- ^ "Zetonna- ciclesonide aerosol, metered". DailyMed. 16 February 2023. Retrieved 29 June 2024.
- ^ "Aservo Equihaler- ciclesonide spray, metered". DailyMed. 16 September 2021. Retrieved 29 June 2024.
- ^ "Aservo Equihaler EPAR". European Medicines Agency. 28 February 2020. Retrieved 29 June 2024.
- ^ Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–1664. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
- ^ "FDA News Release. FDA Approves New Treatment for Allergies". Food and Drug Administration. 23 October 2006. Retrieved 30 July 2009.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Further reading
- Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3.
